What is the Purpose of this Study?
The purpose of this study is to learn whether an experimental drug called sacituzumab govitecan (also called SG or Trodelvy) can help patients with endometrial cancer that has spread or recurred to live longer compared to standard chemotherapy (doxorubicin or paclitaxel). The study focuses on people with endometrial cancer that has returned or worsened during or after previous treatment. Researchers will collect information about the side effects and benefits of SG, doxorubicin, and paclitaxel, in addition to information about participants’ quality of life and other supporting data. Participants in this clinical trial will be randomly assigned to receive SG or the standard chemotherapy study (either doxorubicin or paclitaxel, to be decided by the patient and study doctor).
Eligibility
- * Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).
- * Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.
- * Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.
- * Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center
More about this Clinical Trial
What is the full name of this clinical trial?
GS-US-682-6769/GOG-3104: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy